InterMune Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Brisbane CA United States (1998)
Status: Acquired by Roche (2014)

Organization Overview

First Clinical Trial
2000
NCT00012467
First Marketed Drug
2014
pirfenidone (esbriet)
First NDA Approval
2014
pirfenidone (esbriet)
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Intermune | InterMune Deutschland GmbH

Indications

Approved Indications


 

Idiopathic Pulmonary Fibrosis

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Colorectal Neoplasms (Phase 2)

Communicable Diseases (Phase 2)

Cystic Fibrosis (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Fibrosis (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 3)

Hepatitis, Chronic (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 3)

Infections (Phase 2)

Liver Cirrhosis (Phase 2)

Lung Diseases (Phase 3)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Meningitis (Phase 2)

Meningitis, Cryptococcal (Phase 2)

Ovarian Neoplasms (Phase 2)

Pulmonary Fibrosis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 22
  • # of Trial APIs: 19